Fireside Chat with Dyne Therapeutics on DYNE-251

Moving from Bench to Clinic to Deliver a Potentially Transformative Therapy for Duchenne Muscular Dystrophy

Join us for a Fireside Chat discussing Dyne’s Phase 1/2 clinical trial, DELIVER, evaluating DYNE-251 for the treatment of individuals with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.


Richard S. Finkel, MD 

Director, Center for Experimental Neurotherapies
St. Jude Children’s Research Hospital 

Ashish Dugar, PhD, MBA 

Senior Vice President, Global Head of Medical Affairs 
Dyne Therapeutics 

Molly White 

VP, Global Head of Patient Advocacy and KOL Engagement 
Dyne Therapeutics 

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.